Taken all together, according to the aforementioned evidence, the combinatorial therapy of decitabine, vorinostat, and DPN implied retaining the anti-tumor effect of ERβ as a result of induced ERβ overexpression and activation in the presence of ERα in MDA-MB231 TNBC cells. This evidence concerns the gene ESR2 and neoplasm.